Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy
نویسندگان
چکیده
منابع مشابه
Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy.
BACKGROUND Women with multiple sclerosis (MS) are advised to discontinue interferon-beta therapy before trying to conceive. Unplanned pregnancies occur and risks related to exposure remain unclear. METHODS To determine pregnancy outcomes following interferon-beta therapy, we examined pregnancies from a global drug safety database containing individual case safety reports received in the post-...
متن کاملPregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis.
BACKGROUND Although patients with multiple sclerosis (MS) are advised to stop interferon (IFN) beta-1a therapy before becoming pregnant, some patients become pregnant while on treatment. METHODS We examined individual patient data from eight clinical trials with IFNbeta-1a. RESULTS Of 3,361 women in the studies, 69 pregnancies were reported, of which 41 were patients receiving (or who had s...
متن کاملFingolimod versus High Dose Interferon Beta-1a in Multiple Sclerosis: A Randomized Clinical Trial
Background: High dose Interferon Beta and Fingolimod are efficient in Multiple Sclerosis. Objectives: Comparison the efficacy of these two drugs in patients with treatment failure on low dose interferon beta. Materials and Methods: The MS patients (McDonald criteria 2010) with the history of unbeneficial treatment on low dose interferon beta participated in this randomized clinical trial ...
متن کاملEfficacy of interferon beta-1a in Iranian multiple sclerosis
Objective: To evaluate the clinical efficacy of onceweekly intramuscular interferon beta-1a (IFN B1a, Avonex Biogen) in Iranian multiple sclerosis (MS) patients. Methods: A 12 months, single blind clinical trial conducted from January 2001 to September 2003. Eighty patients with definite MS age 20 to 50 years were allocated to two groups. The first group received 30 microgram (6MIU) IFN B1a wee...
متن کاملAlemtuzumab vs. interferon beta-1a in early multiple sclerosis.
BACKGROUND Alemtuzumab, a humanized monoclonal antibody that targets CD52 on lymphocytes and monocytes, may be an effective treatment for early multiple sclerosis. METHODS In this phase 2, randomized, blinded trial involving previously untreated, early, relapsing-remitting multiple sclerosis, we assigned 334 patients with scores of 3.0 or less on the Expanded Disability Status Scale and a dis...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Multiple Sclerosis Journal
سال: 2011
ISSN: 1352-4585,1477-0970
DOI: 10.1177/1352458510394610